Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Venclyxto and MabThera combo gets approval in Europe for CLL
The approval allows more patients to be treated with Venclyxto in the second-line setting while giving healthcare providers the ability to prescribe the drug to a larger population
The approval allows more patients to be treated with Venclyxto in the second-line setting while giving healthcare providers the ability to prescribe the drug to a larger population
Under the multi-year collaboration, Tango will perform target discovery and validation and Gilead will have options to worldwide rights on up to five targets emerging from Tango’s proprietary
Fostemsavir, in combination with optimised background treatment (OBT), maintained virologic suppression from Week 24 to Week 48 in this difficult-to-treat population. Results show 54% of patients in the
The approval paves way for the use of Hyrimoz in the treatment of rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA) in patients four years of age and older,
The Frederick campus houses a recently expanded east coast distribution center, new Cryo-Innovation Center and the National Cancer Institute Central Repository for Clinical Trials. The site will help
Terns president and CEO Weidong Zhong said: “Since we launched the company a short time ago, we have been working diligently to advance our key programs and continue
For Nexium, which is used in the treatment of gastroesophageal reflux disease, ulcers, and Zollinger-Ellison syndrome, Grünenthal will be acquiring the prescription medicine rights in Europe, which will
The companies will utilize Dicerna’s proprietary GalXC RNAi technology platform to progress new drug targets toward clinical development and commercialization. In addition, the partners will collaborate to move
The companies will conduct both non-clinical and Phase 1 clinical studies of Pfizer’s investigational therapies, including an Acetyl CoA-Carboxylase (ACC) Inhibitor (PF-05221304, currently in Phase 2), a Diacylglycerol
Karo Pharma develops and markets products for pharmacies and also directly to the healthcare sector. The specialty pharma company is said to have a strong presence in the